



Used in Lieu of PTO/SB/08A/B  
(Based on PTO 10-07 version)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/594,778
				Filing Date	September 29, 2006
				First Named Inventor	Peter Lay
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	66366US(54086)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-5,466,824	11-14-1995	Regtop et al.	
	AB*	US-4,287,190	09-01-1981	Boettcher et al.	
	AC*	US-5,310,936	05-10-1994	Regtop et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
	BA	WO-2004/000215	12-31-2003			✓
	BB	WO-90/14337	11-29-1990			✓

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					T <sup>2</sup>
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CA	Weder, Jane Elizabeth, "Characterisation of Copper (II) Dimers of the Non-Steroidal Anti-Inflammatory Drug Indomethacin," A Thesis Submitted in Partial Fulfillment of the Requirements for Admission to the degree of Doctor of Philosophy, School of Inorganic Chemistry, The University of Sydney, 2000.			
	CB	Forsyth, S.F. et al., "Endoscopic Evaluation of the Gastroduodenal Mucosa Following Non-Steroidal Anti-Inflammatory Drug Administration in the Dog," New Zealand Veterinary Journal 44, 1996, pages 179-181.			
	CC	Roch-Arveiller, M. et al., "Effects of some non-steroidal anti-inflammatory drug copper complexes on polymorphonuclear leukocyte oxidative metabolism," Agents and Actions 31, 1990, pages 65-71.			
	CD	Roch-Arveiller, M. et al., "Non-steroidal anti-inflammatory drug-copper complex modulation of polymorphonuclear leucocyte migration," Biochemical Pharmacology 39(3): 1990, pages 569-574.			
	CE	Amico-Roxas, M. et al., "Attivita' Antiinfiammatoria Dell'Indometacina Per Applicazione Topica," European Review for Medical & Pharmacological Sciences, IV, pages 199-204.			
	CF	Zhou, Q. et al., "Syntheses and Characterization of Anti-inflammatory Dinuclear and Mononuclear Zinc Indomethacin Complexes, Crystal Structures of [Zn2(Indomethacin)4(L)2] (L=N, N-Dimethylacetamide, Pyridine, 1-Methyl-2-pyrrolidinone) and [Zn(Indomethacin)2(L1)2]z9z11= Ethanol, Methanol," (2000) Inorg. Chem. 39, pages 3742-3748.			
	CG	Weder, J.E. et al., "Anti-inflammatory Dinuclear Copper (II) complexes with indomethacin. Synthesis, magnetism and EPR Spectroscopy; Crystal Structure of the N, N-Dimethylformamide adductm" Inorg. Chem. 38, pages 1736-1744.			
	CH	Morgan, Y.R. et al., "Preparation and characterization of dinuclear copper-indomethacin anti-inflammatory drugs," Inorg. Chem. 324, pages 150-161.			
Examiner Signature				Date Considered	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/594,778		
		Filing Date	September 29, 2006		
		First Named Inventor	Peter Lay		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	66366US(54086)

CI	Pashley, R.M. (2003), "Effect of degassing on the formation and stability of surfactant-free emulsions and fine teflon dispersions," J. Phys. Chem. 107, pages 1714-1720.
CJ	Warwick, B. et al., "Micronization of copper indomethacin using gas antisolvent processes," Ind. Eng. Chem. Res. 41, pages 1993-2004.
CK	Winter, C. A. et al., "Reaction thresholds to pressure in edematous hindpaws of rats and responses to analgesic drugs," Pharmacol. Exp. Ther. 150, pages 165-171.
CL	Boyle, E. et al., "The role of copper in preventing gastrointestinal damage by acidic anti-inflammatory drugs," J. Pharm. Pharmac. 28, pages 865-868.
CM	Peters, G. E. et al., (1987), "Effects of sodium 5-methoxysalicylate on macromolecule absorption and mucosal morphology in a vascularly perfused rat gut preparation in vivo," J. Pharm. Sci. 76, pages 857-861.
CN	Sorenson, J. R. J. (1989), "Copper complexes offer a physiological approach to treatment of chronic diseases," Prog. Med. Chem. 26, pages 437-568.
CO	Konstandinidou, M. et al., "Anti-inflammatory properties of diclofenac transition metalloelement complexes," Journal of Inorganic Biochemistry, vol. 70, no. 1, 1998, pages 63-69.
CP	Kovala-Demertzi, D. et al., "Metal ion-drug interactions. Preparation and properties of manganese (II), cobalt (II) and nickel (II) complexes of diclofenac with potentially interesting anti-inflammatory activity: Behaviour in the oxidation of 3,5-di-tert-butyl-o-catechol," Journal of Inorganic Biochemistry, vol. 69, no. 4, 1998, pages 223-229.
CQ	Guessous, F. et al., "Ternary copper (II) complexes with indomethacin, a potent non-steroidal anti-inflammatory drug, crystal structure of bis (diethylformamide)-tetrakis [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1-H-indole-3-acetato dicopper (II). Antiinflammatory properties and prevention of gastrointestinal side effects by Nanocapsulesm," Metak-Based Drugs, vol. 5, no. 6, 1998, pages 337-345.
CR	Database Embase [Online] Elsevier Science Publishers, Amsterdam, NL; 1999, Jain N K et al: Analgesic anti-inflammatory and ulcerogenic activity of a zinc-naproxen complex in mice and rats, Database accession no. EMB-1999389902 (Abstract) & Pharmacy and Pharmacology Communications 1999, United Kingdom, vol. 5, no. 10m 1999m oages 599-602.
CS	Greenway, F.T. et al., "Copper (II) complexes of a nonsteroidal anti-inflammatory drug niflumic acid. Synthesis, crystal structure of tetrakis - (2-[3-(trifluoromethyl)phenyl]aminonicotinato) bis (dimethylsulfoxide)- dicopper (II) complex at 190K, Anti-inflammatory properties," Journal of Inorganic Biochemistry, vol. 76, no. 1, 1999, pages 19-27.
CT	Underhill, A.E. et al., "Metal complexes of anti-inflammatory drugs. Part VIII: Suprofen complex of copper (II)," Journal of Inorganic Biochemistry, vol. 52, no. 2, 1993, pages 139-144.
CU	Theodorou, A. et al., "Copper (II) complexes of diclogenac: Spectroscopic studies and DNA strand breakage," Biometals, vol. 12, no. 2, 1999, pages 167-172.
CV	Kovala-Demertzi, D., "Transition metal complexes of diclofenac with potentially interesting anti-inflammatory activity," Journal of Inorganic Biochemistry, vol. 79, no. 1-4, 2000, pages 153-157.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--